PRESS RELEASE

Acticor Biotech completes a capital increase for a total gross amount of approximately 2.6 million euros, via the issuance of 850,360 shares

Paris, France, November 28, 2023 – 8:00 am CET - ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT - the "**Company**"), a clinical-stage biotechnology company developing glenzocimab, a novel drug for the treatment of cardiovascular emergencies, in particular stroke, announces today the completion of its capital increase for a total gross amount of approximately 2.6 million euros, by issuing 850,360 new shares at a price of €3 per share.

Gilles AVENARD, Chief Executive Officer of Acticor Biotech, said: *"I would like to express my gratitude to Mr. Rinaldo del Bono and Mr. Pierre Meyers, for their participation in this fundraising. We also received invaluable support from institutional investors, as well as from numerous individual investors via the PrimaryBid platform. We would like to thank them warmly for the confidence they have placed or renewed in Acticor Biotech. Rest assured that we will continue to pursue with determination our mission to bring to market an innovative drug for the treatment of cardiovascular emergencies."*

Purpose of the funds raised

The funds raised will enable the Company to strengthen its financial structure and finance its operations until May 2024, based on the following elements on the following basis:

- Net cash and cash equivalents (including bank overdrafts) amounting to € 7,955 K at June 30, 2023;
- Cash consumption by the Company's operations in the second half of 2023, and projected cash consumption forecasts for 2024;
- Ability of the Company to pre-finance its 2023 CIR;
- The Company's ability to modulate its variable operating expenses as part of its trials

In addition, in view of the above-mentioned factors, the Company's financing requirements to meet its obligations over the next 12 months are estimated at around 8 million euros.

As a result, the Company will have to seek other sources of debt or equity financing or carry out partnership or M&A transactions as early as the first quarter of 2024, in order to supplement its working capital requirements and finance its operating expenses beyond the second quarter of 2024.

The Company will use the proceeds of this capital increase to finalize the development plan for **the registration of glenzocimab in the emergency treatment of stroke**. The Company mainly plans to use the funds raised to finance the completion of the ACTISAVE study, with results expected in the second quarter of 2024.

Main characteristics of the Offer

The Offer, for a total amount, including issue premium, of approximately 2.6 million euros, was carried out through the issue, without preferential subscription rights and without a priority subscription period, of 850,360 new ordinary shares, as part of:

- a global placement (the "**Global Placement**") of 708,999 new ordinary shares, without pre-emptive subscription rights, with institutional investors for a total amount (including issue premium) of approximately 2.2 million euros, in France and abroad;

- a public offering (the "**PrimaryBid** Offer") of 141,361 new ordinary shares, without pre-emptive subscription rights, to retail investors via the PrimaryBid platform, for an amount (including issue premium) of approximately 0.4 million euros.

The new ordinary shares, representing approximately 6.9% of the Company's share capital, on a non-diluted basis, before completion of the Offer and 6.4% of the Company's share capital, on a non-diluted basis, after completion of the Offer, were issued yesterday evening by decisions of the Company's Chief Executive Officer pursuant to the sub-delegations of authority granted by the Company's Board of Directors on November 22, 2023, in accordance with the 12th and 14th resolutions of the Company's General Meeting of May 12, 2023 (the "**AGM**").

The issue price of the new ordinary shares has been set at €3 per share, representing a discount of 18.48% compared with the closing price of ACTICOR BIOTECH shares on November 27, 2023, i.e. €3.68 and 19.81% compared with the volume-weighted average price of ACTICOR BIOTECH shares on the Euronext Growth multilateral trading facility over the last 3 trading days prior to its setting (i. i.e. November 23, 24 and 27, 2023 inclusive), i.e. €3.7413, in accordance with the decision of the Chief Executive Officer acting by sub-delegation and the resolutions of the above-mentioned General Meeting.

It is specified that Mr. Rinaldo del Bono did not participate in the vote conferring on the Chief Executive Officer the power to launch the Offer and set the final terms thereof.

To the best of the Company's knowledge, the breakdown of shareholders before and after completion of the Offer is as follows:

	Pre-Offer (non-diluted basis)		**Post-Offer (non-diluted basis)**	
	Number of shares	% of capital	Number of shares	% of capital
Mr. Gilles Avenard (Chief Executive Officer and Director)[1]	143,664	1.16%	143,664	1.09%
Mr. Alain Munoz (Director)	14,705	0.12%	14,705	0.11%
M. Jean-Pierre Cazenave (Director) and ARMESA	1,404	0.01%	1,404	0.01%
FPCI CAP DECISIF 3 (Director)	925,530	7.50%	925,530	7.02%
NEWTON BIO CAPITAL I PRICAF PRIVEE SA (Director)	1,556,480	12.61%	1,556,480	11.80%
GO CAPITAL AMORCAGE II (Director)	767,689	6.22%	767,689	5.82%
MEDIOLANUM FARMACEUTICI S.p.A and Mr. Del Bono (Director)[2]	3,403,944	27.59%	3,737,277	28.34%
A&B (HK) LIMITED (censor)	733,049	5.94%	733,049	5.56%
Total Directors and Managers	7,546,465	61.16%	7,879,798	59.74%
CMS MEDICAL VENTURE INVESTMENT (HK) LIMITED	733,049	5.94%	733,049	5.56%
Total investment funds	733,049	5.94%	733,049	5.56%
Own shares held as of November 24, 2023	58,724	0.48%	58,724	0.45%
Free float	4,000,543	32.42%	4,517,570	35.25%
Total	12,338,781	100%	13,189,141	100%

Mr. Rinaldo del Bono, founder of Mediolanum farmaceutici, and the Belgium company M3[3] subscribed to the Global Placement for a total cash amount of 1.5 M€.

These investors represent approximately 59% of the Offer amount.

[1] *This includes the stake held by Gilles Avenard Biotech Consulting (GABC), a consulting company of which Mr. Gilles Avenard is Chairman and sole shareholder.*

[2] *Mediolanum Farmaceutici S.p.A is not a director of the Company, but its Chairman and founder, Mr. Rinaldo Del Bono, is a member of the Company's Board of Directors. For the sake of completeness, the shareholdings of Mediolanum Farmaceutici S.p.A are listed among those of the members of the Board of Directors. As a result of his personal subscription to the Offer, Mr. Rinaldo Del Bono will hold, upon completion of the Offer, 333,333 shares in the Company, for a total of 3,737,277 shares if his shareholding is added to that of Mediolanum Farmaceutici S.p.A.*

[3] *A simple partnership under Belgian law (company number 0721.409.784) of which Mr Pierre Meyers is managing director and majority shareholder.*

Admission of new ordinary shares

Settlement and delivery of the new ordinary shares and their admission to trading on Euronext's Euronext Growth multilateral trading facility in Paris are scheduled for November 30, 2023. The new ordinary shares will be listed on the same quotation line as the Company's existing ordinary shares, will carry dividend rights and will be immediately assimilated to the Company's existing shares.

The Offer does not give rise to a prospectus subject to approval by the Autorité des marchés financiers.

Abstention commitment

In connection with the Offer, the Company has undertaken to abstain from trading for a period of 60 days from the settlement-delivery date of the Offer, subject to customary exceptions.

Conservation commitments

In connection with the Offer, the Board of Directors, executives and certain shareholders, namely Gilles Avenard, Yannick Pletan, Sophie Binay, Alain Munoz, Jean-Pierre Cazenave, Armesa foundation, Patricia Zilliox, Karista (FPCI Cap Décisif 3), Newton Biocapital, Go Capital and Mediolanum Farmaceutici S.p.A., have undertaken to retain the shares they hold to date, representing a total of 55% of the capital after completion of the Offer (on a non-diluted basis), subject to customary exceptions, for a period of 180 calendar days.

Financial Intermediaries

GILBERT DUPONT (Société Générale Group) acted as sole Global Coordinator, Lead Manager and Bookrunner.

Within the framework of the PrimaryBid Offer, investors subscribed only via the PrimaryBid partners mentioned on the PrimaryBid website (www.PrimaryBid.fr).

Guarantee of the Offer

The Offering has not been underwritten. However, the Global Offering made to qualified investors pursuant to the 14th resolution of the Combined General Meeting of May 12, 2023 was the subject of a placement agreement between the Company and the Global Coordinator, Lead Manager and Bookrunner.

The PrimaryBid Offer has not been the subject of a placement and underwriting agreement.

Risk factors

The public's attention is drawn to the risk factors relating to the Company and its business, presented in chapter 3 of the universal registration document 2022 approved by the Autorité des marchés financiers on April 26, 2023 under number R. 22 - 011, which is available free of charge on the Company's website (www.acticor-biotech.com) and the website of the Autorité des marchés financiers (www.amf-france.org). The occurrence of any or all of these risks could have an adverse effect on the Company's business, financial situation, results, development or prospects.

In addition, investors are invited to consider the following risks specific to the issue: (i) the market price of the Company's shares could fluctuate and fall below the subscription price of the shares issued under the Offer, (ii) the volatility and liquidity of the Company's shares could fluctuate significantly, (iii) sales of the Company's shares could occur on the market and have an unfavorable impact on the Company's share price, (iv) the Company's shareholders could suffer potentially significant dilution as a result of any future capital increases made necessary by the Company's search for financing, and (v) as the securities are not intended to be listed on a regulated market, investors will not benefit from the guarantees associated with regulated markets.

About ACTICOR BIOTECH

Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke.

Positive results from its Phase 1b/2a study, ACTIMIS, confirmed the safety profile and showed a reduction in mortality and intracerebral haemorrhage in the glenzocimab-treated group of stroke patients. The efficacy of glenzocimab is currently being evaluated in a Phase 2/3 international trial, ACTISAVE, with clinical results expected in Q2 2024.

In July 2022, Acticor Biotech obtained "PRIME" status from the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation enables the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is backed by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).

For further information, please visit : www.acticor-biotech.com

Contacts

ACTICOR BIOTECH
Gilles AVENARD, MD
General Manager and founder
gilles.avenard@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD
Chief Operating Officer and
Scientific Director
Sophie.binay@acticor-biotech.com
T. : +33 (0)6 76 23 38 13

NewCap
Mathilde BOHIN
Investor Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 94 95

NewCap
Arthur ROUILLÉ
Media Relations
acticor@newcap.eu
T. : +33 (0)1 44 71 00 15

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy ordinary shares of the Company, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the "**Prospectus Regulation**").

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Australia or Japan. This press release does not constitute an offering document and is for information purposes only.

In France, the Offering described above will take place solely as (i) a global placement to qualified investors or a limited number of investors, pursuant to Article L. 411-2, 1° of the French Monetary and Financial Code and applicable regulations, and (ii) a global placement to qualified investors or a limited number of investors, pursuant to Article L. 411-2, 1° of the French Monetary and Financial Code and applicable regulations and (ii) a public offering of securities without a named beneficiary, pursuant to Article L. 225-136 of the French Commercial Code, Article L.411.2-1,1° of the Monetary and Financial Code and applicable regulations.

With respect to Member States of the European Economic Area (including France), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release which would require the publication of a prospectus (pursuant to article 3 of the Prospectus Regulation) in any Member State.

This press release and the information it contains is not an offer to sell, nor the solicitation of an offer to subscribe for or buy, new ordinary shares in the United States or any other jurisdiction where restrictions may apply including notably Canada, Australia or Japan. Securities may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration thereunder. Acticor Biotech does not intend to conduct a public offering of the new ordinary shares in the United States, or in any other jurisdiction.

This communication is being distributed only to, and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"), and (c) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "**Relevant Persons**"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this communication or any of its contents.

Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the new ordinary shares has led to the conclusion in relation to the type of clients criteria and only that: (i) the type of clients to whom the new ordinary shares are targeted is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended ("**MiFID II**"); and (ii) all channels for distribution of the new ordinary shares to eligible counterparties, professional clients and retail clients are appropriate. Any person subsequently offering, selling or recommending the new ordinary shares (a "**Distributor**") should take into consideration the manufacturers' type of clients assessment; however, a Distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the new ordinary shares (by either adopting or refining the manufacturers' type of clients assessment) and determining appropriate distribution channels. For the avoidance of doubt, even if the target market includes retail clients, the sole global coordinator and bookrunner has decided it will only procure investors for the new ordinary shares who meet the criteria of eligible counterparties and professional clients.

This distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.

This press release has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of any of the sole global coordinator and bookrunner or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this press release and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this press release is subject to verification, correction, completion and change without notice.

The sole global coordinator and bookrunner is acting exclusively for the Company and no one else in connection with the Global Placement and will not regard any other person (whether or not a recipient of this press release) as its client in relation to the Global Placement and will not be responsible to anyone other than the Company for providing the protections afforded to its client nor for providing advice in relation to the proposed Global Placement.